THERAPEUTIC EFFECTS OF FLUDARABINE-CYCLOPHOSPHAMIDE COMBINED THERAPY IN IRANIAN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MOSHFEGHI KAMRAN; MOSAYEBI GHASEM

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Koomesh Year:2015 | Volume:16 | Issue:2 (54) Page(s): 202-206

Download Full-Text

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

View:

1,160

Download:

Cites:

Information Journal Paper

Title

THERAPEUTIC EFFECTS OF FLUDARABINE-CYCLOPHOSPHAMIDE COMBINED THERAPY IN IRANIAN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA

Author(s)

MOSHFEGHI KAMRAN | MOSAYEBI GHASEM | Issue Writer Certificate

Keywords

LEUKEMIAQ2

LYMPHOCYTICQ2

CHRONICQ2

B-CELLQ2

CYCLOPHOSPHAMIDEQ2

FLOW CYTOMETRYQ2

Abstract

Introduction: The aim of this study was to investigate the efficacy of fludarabine-cyclophosphamide combination in treatment of Iranian patients with B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL).Materials and Methods: Between April 2011 and July 2013, 20 patients with B-CLL (median age 63 years) received a regimen that consisted of fludarabine 25 mg/m2 and CYCLOPHOSPHAMIDE 250 mg/m2, days 1-3, orally, every 4 weeks, for a maximum of 6 courses. Clinical appearances and percentage of CD5+/CD19+ cells as minimal residual disease detected by FLOW CYTOMETRY before and 6 months after treatment.Results: The frequency of CD5+, CD5+/CD19+ and CD19+-cells were significantly high (70-90 %) in the peripheral blood of all the patients, before treatment. The percentage of CD2 and CD3+-cells were significantly increased after treatment (p<0.0001). There were significantly different in the percentage of CD5+/CD19+-cells before (68±26) and after (35±23) treatment (p=0.001). Also, the clinical features were modulated after treatment.Conclusion: The results showed that combination of fludarabine and CYCLOPHOSPHAMIDE could be helpful in treatment of B-CLL in Iranian patients.

Cites

References

No record.

Cite

APA: Copy

MOSHFEGHI, KAMRAN, & MOSAYEBI, GHASEM. (2015). THERAPEUTIC EFFECTS OF FLUDARABINE-CYCLOPHOSPHAMIDE COMBINED THERAPY IN IRANIAN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. KOOMESH, 16(2 (54)), 202-206. SID. https://sid.ir/paper/37152/en

Vancouver: Copy

MOSHFEGHI KAMRAN, MOSAYEBI GHASEM. THERAPEUTIC EFFECTS OF FLUDARABINE-CYCLOPHOSPHAMIDE COMBINED THERAPY IN IRANIAN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. KOOMESH[Internet]. 2015;16(2 (54)):202-206. Available from: https://sid.ir/paper/37152/en

IEEE: Copy

KAMRAN MOSHFEGHI, and GHASEM MOSAYEBI, “THERAPEUTIC EFFECTS OF FLUDARABINE-CYCLOPHOSPHAMIDE COMBINED THERAPY IN IRANIAN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA,” KOOMESH, vol. 16, no. 2 (54), pp. 202–206, 2015, [Online]. Available: https://sid.ir/paper/37152/en

Related Journal Papers